GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis

Sponsor
University Hospital, Gentofte, Copenhagen
Study ID
NCT01451905
Status
Unknown

Conditions

  • Reduction of Psoriasis Following Liraglutide Therapy in Terms of PASI and DLQI

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide — DRUG
    Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylene glycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.
  • Placebo — DRUG
    The placebo pens contain saline and are administered in the same way and volume as Victoza. The placebo pens are specially prepared for this study and will be used in the study only

Study Details

To examine GLP-1 receptors in skin of psoriasis patients compared with the skin of humans with no skin disease

Key Dates

Start date
Aug 31, 2011
Status verified
Jun 2012
Primary completion
Dec 31, 2012
Completion
Dec 31, 2012

Study Design

Enrollment
12 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL

Arms

  • Active Comparator: Psoriasis
  • Placebo Comparator: Placebo

Primary Outcome Measure

Changes in PASI and DLQI [ Time Frame: 2 months ]

Central Contacts

  • Annesofie Faurschou, MD PhD
    +45 39773977